A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
2 other identifiers
interventional
200
4 countries
38
Brief Summary
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_2 obesity
Started Oct 2025
38 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 9, 2025
CompletedFirst Posted
Study publicly available on registry
October 10, 2025
CompletedStudy Start
First participant enrolled
October 16, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 1, 2027
March 2, 2026
February 1, 2026
1.4 years
October 9, 2025
February 27, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percent Change from Baseline in Body Weight
Baseline, Week 32
Secondary Outcomes (3)
Change from Baseline in Hemoglobin A1c (HbA1c)
Baseline, Week 32
Change from Baseline in Body Mass Index (BMI)
Baseline, Week 32
Change from Baseline in Fasting Glucose
Baseline, Week 32
Study Arms (4)
Macupatide (Macupatide + Eloralintide Placebo)
EXPERIMENTALParticipants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC
Eloralintide (Elorlintide + Macupatide Placebo)
EXPERIMENTALParticipants will be administered eloralintide SC and macupatide placebo SC
Macupatide + Eloralintide
EXPERIMENTALParticipants will be administered eloralintide SC and macupatide SC
Placebo (Macupatide Placebo + Elorlintide Placebo)
PLACEBO COMPARATORParticipants will be administered eloralintide placebo SC and macupatide placebo SC
Interventions
Administered SC
Administered SC
Administered SC
Administered SC
Eligibility Criteria
You may qualify if:
- Have type 2 diabetes
- Have an HbA1c ≥7.5% to ≤10.5% at screening
- Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening
- Diet and exercise
- Stable dose of metformin
- Sodium-glucose cotransporter-2 (SGLT2) inhibitor
- Have had a stable body weight (\<5% body weight gain and/or loss) for the 3 months prior to screening
- Have a BMI of 27 or greater at screening
You may not qualify if:
- Have any form of diabetes other than type 2 diabetes
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \>1 year prior to screening
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include
- basal or squamous cell skin cancer
- in situ carcinomas of the cervix, or
- in situ prostate cancer
- Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:
- amylin RA
- dual amylin and calcitonin RA
- glucagon-like peptide-1 receptor (GLP-1) RA
- +5 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (38)
Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
Gilbert, Arizona, 85296, United States
Synexus Clinical Research US, Inc.
Phoenix, Arizona, 85020, United States
Pima Heart
Tucson, Arizona, 85741, United States
SKY Clinical Research Network Group-Brown
Atlanta, Georgia, 30331, United States
Teak Research Consults
Lawrenceville, Georgia, 30043, United States
AGILE Clinical Research Trials, LLC
Sandy Springs, Georgia, 30328, United States
Pivotal Research Solutions
Stonecrest, Georgia, 30038, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, 30291, United States
Vector Clinical Trials
Las Vegas, Nevada, 89128, United States
Premier Research
Trenton, New Jersey, 08611, United States
Mercy Family Clinic
Dallas, Texas, 75208, United States
Velocity Clinical Research, Dallas
Dallas, Texas, 75230, United States
PlanIt Research, PLLC
Houston, Texas, 77079, United States
Aavon Clinical Trials
Richmond, Texas, 77407, United States
Consano Clinical Research, LLC
Shavano Park, Texas, 78231, United States
Texas Valley Clinical Research
Weslaco, Texas, 78596, United States
Kalo Clinical Research
West Valley City, Utah, 84120, United States
Eastern Virginia Medical School (EVMS) Medical Group
Norfolk, Virginia, 23510, United States
Clinical Research Partners, LLC
Richmond, Virginia, 23226, United States
Northwest Clinical Research Center
Bellevue, Washington, 98007, United States
Rainier Clinical Research Center
Renton, Washington, 98057, United States
Universal Research Group
Tacoma, Washington, 98405, United States
Centro de Investigaciones Metabólicas (CINME)
Buenos Aires, C1056ABI, Argentina
CENUDIAB
Buenos Aires, C1440AAD, Argentina
CEDIC
CABA, C1060ABN, Argentina
Instituto de Investigaciones Clínicas Córdoba
Córdoba, 5000, Argentina
Clínica Universitaria Reina Fabiola
Córdoba, X50004FHP, Argentina
Go Centro Medico San Nicolás
San Nicolás, 2900, Argentina
Emeritus Research
Botany, 2019, Australia
Core Research Group
Brisbane, 4064, Australia
Emeritus Research
Camberwell, 3124, Australia
Cornerstone Dermatology
Coorparoo, 4151, Australia
Momentum Darlinghurst
Darlinghurst, Sydney, 2010, Australia
CDH Research Institute Pty Ltd
Maroochydore, 4558, Australia
Momentum Sunshine
Melbourne, 3021, Australia
AIM Research
Merewether, 2291, Australia
San Juan Bautista School of Medicine - Clinical Research Unit
Caguas, 00726, Puerto Rico
Mgcendo Llc
San Juan, 00921, Puerto Rico
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Central Study Contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 9, 2025
First Posted
October 10, 2025
Study Start
October 16, 2025
Primary Completion (Estimated)
March 1, 2027
Study Completion (Estimated)
May 1, 2027
Last Updated
March 2, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
- Access Criteria
- A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.